Desktop III:A randomized multicenter study to compare the efficacy of additional tumour debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer.
Chief Investigator:
|
Prof David Luesley |
| Sponsor: |
AGO Studiengruppe |
| Funder: |
CTAAC |
| Disease Site: |
OVARY |
| Trial Type: |
Surgery Trial |
| Status: |
On Follow-up |
| UKCRN Study ID (if applicable): |
N/A |
| ISRCTN Referance Number: |
39361386 |
| Open to New Sites? |
No |
| Recruitment Start Date: |
24-Aug-2012 |
| Recruitment End Date: |
25-Mar-2015 |
| CRCTU Trial Management Team: |
Late Phase Trial Management Team- A |
| Trial Email Address: |
desktopiii@trials.bham.ac.uk |
Trial Summary
Approximately two thirds of patients treated for advanced ovarian cancer will relapse within 12 months after completion of primary chemotherapy.
The goal of this study is to determine whether surgery and chemotherapy together is better than chemotherapy alone to treat ovarian cancer that has come back. To answer this question consenting patients will be randomly assigned to either the surgery with chemotherapy or chemotherapy alone. The length of survival and side effects for both groups will be collected and analysed to see which treatment is better.
This is an international trial that follows a protocol developed in Germany.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
Trial Protocol
Please Note:
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial.
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.